Fears about downward pressure on drug prices have helped spur a wave of biolech and pharma acquisitions. But some investors think one biotech giant can keep growing even without a deal. GILEAD SCIENCES has been good to Susan Kempler. Her $5 billion TIAA-CREF Growth & Income Fund bought the stock in 2011, the day after Gilead acquired Pharmasset, a little-known maker of hepatitis C drugs; Three-and-a-half years and two blockbuster drugs later, the shares are up more than 400%.
展开▼
